| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2024―Jul―30 |
The rising SARS-CoV-2 JN.1 variant: evolution, infectivity, immune escape, and response strategies |
Yishan Lu, Danyi Ao, Xuemei He, Xiawei Wei |
| 2 |
[GO] |
2024―Jul―19 |
Decisive reversal of lethal coronavirus disease 2019 in senescent hamster by synchronic antiviral and immunoregulatory intervention |
Xuan Liu, Ming Zhou, Mujing Fang, Ying Xie, Peiwen Chen, Rirong Chen, Kun Wu, Jianghui Ye, Che Liu, Huachen Zhu, Tong Cheng, Lunzhi Yuan, Hui Zhao, Yi Guan, Ningshao Xia |
| 3 |
[GO] |
2024―Jul―14 |
Risk of pulmonary embolism and deep vein thrombosis following COVID-19: a nationwide cohort study |
Hye Jun Kim, Seogsong Jeong, Jihun Song, Sun Jae Park, Young Jun Park, Yun Hwan Oh, Jaehun Jung, Sang Min Park |
| 4 |
[GO] |
2024―Jul―05 |
COVID-19 vaccine: recent advancements and future prospects |
Li Xu, Min Li, Wu He |
| 5 |
[GO] |
2024―Jun―15 |
SARS-CoV-2 Omicron subvariants from BA.2 to BA.2.86 and JN.1: strong lung infection ability and evolving immune escape capacity |
Bixia Hong, Maochen Li, Huahao Fan |
| 6 |
[GO] |
2024―Jun―14 |
Optimization and validation of a virus-like particle pseudotyped virus neutralization assay for SARS-CoV-2 |
Shuo Liu, Li Zhang, Wangjun Fu, Ziteng Liang, Yuanling Yu, Tao Li, Jincheng Tong, Fan Liu, Jianhui Nie, Qiong Lu, Shuaiyao Lu, Weijin Huang, Youchun Wang |
| 7 |
[GO] |
2024―Jun―08 |
Antigenicity and infectivity of severe acute respiratory syndrome coronavirus 2 Omicron subvariants EG.5.1, XBB.2.3, FL.1.5.1, and BA.2.86 |
Haijun Tang, Yanhang Zhuo, Xiaohong Du, Frank Xiao-Feng Qin, Yi Huang |
| 8 |
[GO] |
2024―Apr―28 |
A chimeric adenovirus-vectored vaccine based on Beta spike and Delta RBD confers a broad-spectrum neutralization against Omicron-included SARS-CoV-2 variants |
Weiqi Hong, Hong Lei, Dandan Peng, Yuhe Huang, Cai He, Jingyun Yang, Yanan Zhou, Jian Liu, Xiangyu Pan, Haiying Que, Aqu Alu, Li Chen, Jiayuan Ai, Furong Qin, Binhan Wang, Danyi Ao, Zhen Zeng, Ying Hao, Yu Zhang, Xiya Huang, Chunjun Ye, MinYang Fu, Xuemei He, Zhenfei Bi, Xuejiao Han, Min Luo, Hongbo Hu, Wei Cheng, Haohao Dong, Jian Lei, Lu Chen, Xikun Zhou, Wei Wang, Guangwen Lu, Guobo Shen, Li Yang, Jinliang Yang, Jiong Li, Zhenling Wang, Xiangrong Song, Qiangming Sun, Shuaiyao Lu, Youchun Wang, Ping Cheng, Xiawei Wei |
| 9 |
[GO] |
2024―Apr―01 |
Serotonin signaling: a new player and therapeutic target beyond Long-haul coronavirus disease |
Lan Bai, Fangfang Zhou, Long Zhang |
| 10 |
[GO] |
2024―Mar―22 |
Development of a SARS-CoV-2 neutralization assay based on a pseudotyped virus using a HIV system |
Ziteng Liang, Jincheng Tong, Xi Wu, Shuo Liu, Jiajing Wu, Yuanling Yu, Li Zhang, Chenyan Zhao, Qiong Lu, Jianhui Nie, Weijin Huang, Youchun Wang |
| 11 |
[GO] |
2024―Mar―16 |
Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions |
Yong Qiu, Chunheng Mo, Lu Chen, Wanlin Ye, Guo Chen, Tao Zhu |
| 12 |
[GO] |
2024―Mar―09 |
Current clinical findings of acute neurological syndromes after SARS-CoV-2 infection |
Minjin Wang, Jierui Wang, Yan Ren, Lu Lu, Weixi Xiong, Lifeng Li, Songtao Xu, Meng Tang, Yushang Yuan, Yi Xie, Weimin Li, Lei Chen, Dong Zhou, Binwu Ying, Jinmei Li |
| 13 |
[GO] |
2024―Feb―28 |
Efficacy of small molecules against the severe acute respiratory syndrome coronavirus 2 XBB1.16 and XBB1.9.2.1 |
Lunzhi Yuan, Xuan Liu, Song Li, Wu Zhong, Ningshao Xia |
| 14 |
[GO] |
2024―Feb―28 |
Chronic hepatitis B virus infection deteriorates disease outcome of coronavirus disease 2019 in hamster |
Lunzhi Yuan, Xuan Liu, Yi Guan, Tong Cheng, Ningshao Xia |
| 15 |
[GO] |
2023―Dec―30 |
Immunotherapy against lung cancer does not need to compromise the outcomes of COVID-19 |
Jiadi Gan, Jiaxuan Wu, Huohuo Zhang, Dan Liu, Weimin Li |
| 16 |
[GO] |
2023―Dec―19 |
SARS-CoV-2 booster immunization: stimulating de novo B-cell response and antibody generation |
Qiaonan Hong, Ziyi Bai, Dong Tian |
| 17 |
[GO] |
2023―Nov―21 |
Single-cell transcriptomic atlas of distinct early immune responses induced by SARS-CoV-2 Proto or its variants in rhesus monkey |
Yun Yang, Tingfu Du, Wenhai Yu, Yanan Zhou, Chengyun Yang, Dexuan Kuang, Junbin Wang, Cong Tang, Haixuan Wang, Yuan Zhao, Hao Yang, Qing Huang, Daoju Wu, Bai Li, Qiangming Sun, Hongqi Liu, Shuaiyao Lu, Xiaozhong Peng |
| 18 |
[GO] |
2023―Nov―16 |
Blood-derived product therapies for SARS-CoV-2 infection and long COVID |
Junzheng Wu, Huichuan Yang, Ding Yu, Xiaoming Yang |
| 19 |
[GO] |
2023―Oct―26 |
A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains |
Hebang Yao, Hongyang Wang, Zhaoyong Zhang, Yuchi Lu, Zhiying Zhang, Yu Zhang, Xinyi Xiong, Yanqun Wang, Zhizhi Wang, Haitao Yang, Jincun Zhao, Wenqing Xu |
| 20 |
[GO] |
2023―Oct―12 |
The Apolipoprotein E neutralizing antibody inhibits SARS-CoV-2 infection by blocking cellular entry of lipoviral particles |
Qi Cui, Arjit Vijey Jeyachandran, Gustavo Garcia, Chao Qin, Yu Zhou, Mingzi Zhang, Cheng Wang, Guihua Sun, Wei Liu, Tao Zhou, Lizhao Feng, Chance Palmer, Zhuo Li, Adam Aziz, Brigitte N. Gomperts, Pinghui Feng, Vaithilingaraja Arumugaswami, Yanhong Shi |
| 21 |
[GO] |
2023―Sep―25 |
No genetic causal association between COVID-19 infection, hypogonadism, and male infertility |
Yang Xiong, Xiaokun Hu, Yangchang Zhang, Feng Qin, Jiuhong Yuan |
| 22 |
[GO] |
2023―Sep―24 |
The unique interplay of mitochondrial oxidative phosphorylation (OXPHOS) and immunity and its potential implication for the sex- and age-related morbidity of severe COVID-19 patients |
Yinchuan Li, Lei Li, Guanghao Wu, Gangcai Xie, Lirong Yi, Jie Zhu, ShiYu Liang, Ya-ru Huang, Juan Chen, Shaoyang Ji, Fei Sun, Rui-tian Liu |
| 23 |
[GO] |
2023―Sep―10 |
Prime editor-mediated functional reshaping of ACE2 prevents the entry of multiple human coronaviruses, including SARS-CoV-2 variants |
Wenwen Zhao, Jifang Li, Xiao Wang, Wei Xu, Bao-Qing Gao, Jiangchao Xiang, Yaofeng Hou, Wei Liu, Jing Wu, Qilian Qi, Jia Wei, Xiaoyu Yang, Lu Lu, Li Yang, Jia Chen, Bei Yang |
| 24 |
[GO] |
2023―Sep―03 |
Profiling of SARS-CoV-2 neutralizing antibody-associated antigenic peptides signature using proteome microarray |
Mingkun Wu, Jiangfeng Liu, Xinming Wang, Xiaomei Zhang, Te Liang, Lan Chen, Tingxuan Huang, Yanan Li, Chang Zheng, Yehong Yang, Jianwei Wang, Xiaobo Yu, Li Guo, Juntao Yang, Lili Ren |
| 25 |
[GO] |
2023―Aug―26 |
Proteomic and phosphoproteomic profiling of SARS-CoV-2-associated liver injury: a report based on rhesus macaques |
Xiaoyue Tang, Yanan Zhou, Jianqiang Wu, Peng Liu, Yehong Yang, Qiaochu Wang, Shuaiyao Lu, Jiangfeng Liu, Juntao Yang |
| 26 |
[GO] |
2023―Jul―04 |
Correlations between the viral loads and symptoms in the SARS-CoV-2-infected patients |
Xiaomin Wang, Shaolin Ma, Bing Zhao, Ganxiu Deng, Huiyuan She, Kailiang Xu, Lipeng Hao, Yiming Deng, Qiang Li, Zuoren Yu, Xiaoping Zhu |
| 27 |
[GO] |
2023―Jun―24 |
Vitamin D3 attenuates SARS-CoV-2 nucleocapsid protein-caused hyperinflammation by inactivating the NLRP3 inflammasome through the VDR-BRCC3 signaling pathway in vitro and in vivo |
Mingliang Chen, Ying He, Xiaofeng Hu, Xunhu Dong, Zexuan Yan, Qingning Zhao, Jingyuan Li, Dongfang Xiang, Yong Lin, Hongbin Song, Xiuwu Bian |
| 28 |
[GO] |
2023―Jun―10 |
Risk and outcomes of breakthrough COVID-19 infections in vaccinated immunocompromised patients: A meta-analysis |
Guangtong Deng, Qian Zhou, Yu Meng, Huiyan Sun, Songtao Du, Yihuang Liu, Furong Zeng |
| 29 |
[GO] |
2023―Jun―01 |
A two-step infection model: From SARS-CoV-2 entry and trafficking to egress and spread |
Liting You, Binwu Ying |
| 30 |
[GO] |
2023―May―14 |
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS-CoV-2 |
Yiying Xue, Husheng Mei, Yisa Chen, James D. Griffin, Qingsong Liu, Ellen Weisberg, Jing Yang |
| 31 |
[GO] |
2023―Apr―27 |
A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2 |
Cai He, Aqu Alu, Hong Lei, Jingyun Yang, Weiqi Hong, Xiangrong Song, Jiong Li, Li Yang, Wei Wang, Guobo Shen, Guangwen Lu, Xiawei Wei |
| 32 |
[GO] |
2023―Apr―09 |
COVID-19 in early 2023: Structure, replication mechanism, variants of SARS-CoV-2, diagnostic tests, and vaccine & drug development studies |
Ilker Polatoğlu, Tulay Oncu-Oner, Irem Dalman, Senanur Ozdogan |
| 33 |
[GO] |
2023―Apr―07 |
Neurological damages in COVID-19 patients: Mechanisms and preventive interventions |
Sibani Sarkar, Subhajit Karmakar, Malini Basu, Pratyasha Ghosh, Mrinal K Ghosh |
| 34 |
[GO] |
2023―Mar―20 |
COPD, diabetes, lymphopenia, and increased LDH cause higher mortality in hospitalized COVID-19 patients |
Guilherme C. Frison, Sainan V. da Cunha, Lucas Q. Antoniazzi, Paulo H. K. de Oliveira, Joao P. S. Oliveira, Vinicius F. Cury, Clara Fontanari, Enrico E. Moretto, Verônica A. Oliveira, Renato Seligman |
| 35 |
[GO] |
2023―Mar―15 |
The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants |
Danyi Ao, Xuemei He, Weiqi Hong, Xiawei Wei |
| 36 |
[GO] |
2023―Mar―10 |
Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5-included SARS-CoV-2 variants than homologous vaccination of mRNA vaccine |
Dandan Peng, Tingmei Zhao, Weiqi Hong, Minyang Fu, Cai He, Li Chen, Wenyan Ren, Hong Lei, Jingyun Yang, Aqu Alu, Yanghong Ni, Jian Liu, Jiong Li, Wei Wang, Guobo Shen, Zhiwei Zhao, Li Yang, Jinliang Yang, Zhenling Wang, Yoshimasa Tanaka, Guangwen Lu, Xiangrong Song, Xiawei Wei |
| 37 |
[GO] |
2023―Jan―31 |
CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection |
Zongzhi Liu, Xiang Gao, Chuanwen Kan, Lingyu Li, Yuan Zhang, Yibo Gao, Shengyuan Zhang, Liangji Zhou, Hui Zhao, Mingkun Li, Zheng Zhang, Yingli Sun |
| 38 |
[GO] |
2023―Jan―19 |
Antiviral effects and tissue exposure of tetrandrine against SARS-CoV-2 infection and COVID-19 |
Jia Liu, Furun Wang, Xi Wang, Shiyong Fan, Yufeng Li, Mingyue Xu, Hengrui Hu, Ke Liu, Bohong Zheng, Lingchao Wang, Huanyu Zhang, Jiang Li, Wei Li, Wenpeng Zhang, Zhihong Hu, Ruiyuan Cao, Xiaomei Zhuang, Manli Wang, Wu Zhong |
| 39 |
[GO] |
2022―Dec―09 |
Long COVID: The latest manifestations, mechanisms, and potential therapeutic interventions |
Shi-ting He, Kexin Wu, Zixuan Cheng, Mengjie He, Ruolan Hu, Ning Fan, Lin Shen, Qirui Li, Huahao Fan, Yigang Tong |
| 40 |
[GO] |
2022―Dec―02 |
Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses |
Jialu Zhang, Qian He, Xujia Yan, Jianyang Liu, Yu Bai, Chaoqiang An, Bopei Cui, Fan Gao, Qunying Mao, Junzhi Wang, Miao Xu, Zhenglun Liang |
| 41 |
[GO] |
2022―Dec―02 |
Distribution of intra-host variations and mutations in the genomes of SARS-CoV-2 and their implications on detection and therapeutics |
Dongyan Xiong, Xiaoxu Zhang, Junping Yu, Hongping Wei |
| 42 |
[GO] |
2022―Oct―05 |
The safety and short-term outcomes of allogeneic hematopoietic stem cell transplantation with donor vaccination for COVID-19 |
Yihan Ding, Yifan Shen, Yi Fan, Jia Chen, Yang Xu, Depei Wu |
| 43 |
[GO] |
2022―Sep―30 |
Potential mechanisms by which impaired ketogenesis links metabolism to T-cell dysfunction in patients with severe COVID-19 |
Bin Wang, Lei Zhang, Fangfang Zhou, Long Zhang |
| 44 |
[GO] |
2022―Aug―16 |
Sub-lineages of the SARS-CoV-2 Omicron variants: Characteristics and prevention |
Ailan Xu, Bixia Hong, Fuxing Lou, Shuqi Wang, Wenye Li, Amna Shafqat, Xiaoping An, Yunwei Zhao, Lihua Song, Yigang Tong, Huahao Fan |
| 45 |
[GO] |
2022―Aug―12 |
Down-regulation of SARS-CoV-2 neutralizing antibodies in vaccinated smokers |
Jiahui Zhang, Fei Teng, Xiaomei Zhang, Hongye Wang, Te Liang, Shubin Guo, Xiaobo Yu |
| 46 |
[GO] |
2022―Aug―10 |
COVID-19 metabolism: Mechanisms and therapeutic targets |
Tianshi Wang, Ying Cao, Haiyan Zhang, Zihao Wang, Cheuk Him Man, Yunfan Yang, Lingchao Chen, Shuangnian Xu, Xiaojing Yan, Quan Zheng, Yi-Ping Wang |
| 47 |
[GO] |
2022―Aug―01 |
Inflammatory pathways in COVID-19: Mechanism and therapeutic interventions |
Yujie Jiang, Tingmei Zhao, Xueyan Zhou, Yu Xiang, Pedro Gutierrez-Castrellon, Xuelei Ma |
| 48 |
[GO] |
2022―Jul―25 |
Outbreak control management: Lessons from SARS-CoV-2 infections in 2020-2022 in Hong Kong, an international municipality with high-frequency travelers |
Yaxiu Feng, Ching Han Young, Siu Hin Lau, Ming-Liang He |
| 49 |
[GO] |
2022―Jul―15 |
The SARS-CoV-2 main protease (M
pro
): Structure, function, and emerging therapies for COVID-19 |
Qing Hu, Yuan Xiong, Guang-Hao Zhu, Ya-Ni Zhang, Yi-Wen Zhang, Ping Huang, Guang-Bo Ge |
| 50 |
[GO] |
2022―Jul―11 |
Circular RNA vaccine, a novel mRNA vaccine design strategy for SARS-CoV-2 and variants |
Peng Su, Lei Zhang, Fangfang Zhou, Long Zhang |
| 51 |
[GO] |
2022―May―12 |
Homologous or heterogenous vaccination boosters enhance neutralizing activities against SARS-CoV-2 Omicron BA.1 variant |
Zhongcheng Zhou, Peng Du, Ning Li, Xinxin Xiong, Shengjun Tang, Qinjin Dai, Taorui Wang, Meixing Yu, Miao Man, Kelvin Lam, Daniel T. Baptista-Hon, Wa Hou Tai, Olivia Monteiro, Weng Sam Ng, Un Man Lee, Zhihai Liu, Kang Zhang, Gen Li |
| 52 |
[GO] |
2022―May―02 |
A next-generation vaccine for broader and long-lasting COVID-19 protection |
Jinxiang Xi, Xiuhua April Si |
| 53 |
[GO] |
2022―Apr―09 |
Antigenicity comparison of SARS-CoV-2 Omicron sublineages with other variants contained multiple mutations in RBD |
Qianqian Li, Mengyi Zhang, Ziteng Liang, Li Zhang, Xi Wu, Chaoying Yang, Yimeng An, Jincheng Tong, Shuo Liu, Tao Li, Qianqian Cui, Jianhui Nie, Jiajing Wu, Weijin Huang, Youchun Wang |
| 54 |
[GO] |
2022―Apr―09 |
Characteristic analysis of Omicron-included SARS-CoV-2 variants of concern |
Hao Yang, Penghui Liu, Yong Zhang, Tingfu Du, Yanan Zhou, Shuaiyao Lu, Xiaozhong Peng |
| 55 |
[GO] |
2022―Mar―16 |
SARS-CoV-2 Omicron variant: Immune escape and vaccine development |
Danyi Ao, Tianxia Lan, Xuemei He, Jian Liu, Li Chen, Daniel T. Baptista-Hon, Kang Zhang, Xiawei Wei |
| 56 |
[GO] |
2022―Mar―09 |
Epidemic waves caused by SARS-CoV-2 omicron (B.1.1.529) and pessimistic forecasts of the COVID-19 pandemic duration |
Igor Nesteruk |
| 57 |
[GO] |
2022―Feb―17 |
COVID-19: A systematic review and update on prevention, diagnosis, and treatment |
Hooman Aghamirza Moghim Aliabadi, Reza Eivazzadeh-Keihan, Arezoo Beig Parikhani, Sara Fattahi Mehraban, Ali Maleki, Sepideh Fereshteh, Masoume Bazaz, Ashkan Zolriasatein, Bahareh Bozorgnia, Saman Rahmati, Fatemeh Saberi, Zeinab Yousefi Najafabadi, Shadi Damough, Sara Mohseni, Hamid Salehzadeh, Vahid Khakyzadeh, Hamid Madanchi, Gholam Ali Kardar, Payam Zarrintaj, Mohammad Reza Saeb, Masoud Mozafari |
| 58 |
[GO] |
2022―Feb―11 |
SARS-CoV-2 Omicron variant: A next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine |
Ebrahim Mostafavi, Ankit Kumar Dubey, Laura Teodori, Seeram Ramakrishna, Ajeet Kaushik |
| 59 |
[GO] |
2022―Jan―17 |
SARS-CoV-2 triggered oxidative stress and abnormal energy metabolism in gut microbiota |
Tuoyu Zhou, Jingyuan Wu, Yufei Zeng, Junfeng Li, Jun Yan, Wenbo Meng, Huawen Han, Fengya Feng, Jufang He, Shuai Zhao, Ping Zhou, Ying Wu, Yanlin Yang, Rong Han, Weilin Jin, Xun Li, Yunfeng Yang, Xiangkai Li |
| 60 |
[GO] |
2021―Dec―31 |
Criteria for judging the immune markers of COVID-19 disease vaccines |
Nan Lin, Haoxuan Fu, Dan Pu, Yuxin Quan, Yueyi Li, Xiaomeng Yin, Yuhao Wei, Hang Wang, Xuelei Ma, Xiawei Wei |
| 61 |
[GO] |
2021―Dec―17 |
SARS-CoV-2 Omicron variant: Characteristics and prevention |
Xuemei He, Weiqi Hong, Xiangyu Pan, Guangwen Lu, Xiawei Wei |
| 62 |
[GO] |
2021―Dec―14 |
Nasally inhaled therapeutics and vaccination for COVID-19: Developments and challenges |
Jinxiang Xi, Lameng Ray Lei, William Zouzas, Xiuhua April Si |
| 63 |
[GO] |
2021―Nov―16 |
Animal models for SARS-CoV-2 infection and pathology |
Zhenfei Bi, Weiqi Hong, Jingyun Yang, Shuaiyao Lu, Xiaozhong Peng |
| 64 |
[GO] |
2021―Oct―21 |
The challenges of COVID-19 Delta variant: Prevention and vaccine development |
Xuemei He, Cai He, Weiqi Hong, Kang Zhang, Xiawei Wei |
| 65 |
[GO] |
2021―Oct―21 |
Pulmonary vascular system: A vulnerable target for COVID-19 |
Jiayuan Ai, Weiqi Hong, Min Wu, Xiawei Wei |
| 66 |
[GO] |
2021―Oct―10 |
SARS-CoV-2 spike protein harnesses SNX27-mediated endocytic recycling pathway |
Lin Zhao, Kunhong Zhong, Jia Zhao, Xin Yong, Aiping Tong, Da Jia |
| 67 |
[GO] |
2021―Sep―16 |
Application of omics technology to combat the COVID-19 pandemic |
Jingjing Yang, Yunzheng Yan, Wu Zhong |
| 68 |
[GO] |
2021―Jun―24 |
Potent neutralizing RBD-specific antibody cocktail against SARS-CoV-2 and its mutant |
Lina Jia, Yan-Ping Liu, Li-Fei Tian, Chao Xiong, Xin Xu, Honge Qu, Weixi Xiong, Dong Zhou, Feng Wang, Zheng Liu, Xiao-Xue Yan, Wenqing Xu, Lin Tang |
| 69 |
[GO] |
2021―May―17 |
A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus |
Cai He, Jingyun Yang, Xuemei He, Weiqi Hong, Hong Lei, Zimin Chen, Guobo Shen, Li Yang, Jiong Li, Zhenling Wang, Xiangrong Song, Wei Wang, Guangwen Lu, Xiawei Wei |
| 70 |
[GO] |
2021―Apr―08 |
Sex differences in clinical characteristics and risk factors for disease severity of hospitalized patients with COVID-19 |
Jing-Jing Wang, Yun-Juan Su, Qi Wang, Ying Cao, Ai-Bin Wang, Rui Ding, Wen Xie |
| 71 |
[GO] |
2021―Mar―18 |
Risk factors associated with deep vein thrombosis in COVID-19 patients |
Bin Wang, Li Zhang, Shanye Yin, Wenjun Deng, Mingxing Xie |
| 72 |
[GO] |
2021―Mar―04 |
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential |
Junwei Gai, Linlin Ma, Guanghui Li, Min Zhu, Peng Qiao, Xiaofei Li, Haiwei Zhang, Yanmin Zhang, Yadong Chen, Weiwei Ji, Hao Zhang, Huanhuan Cao, Xionghui Li, Rui Gong, Yakun Wan |
| 73 |
[GO] |
2021―Feb―06 |
COVID-19 infection in patients with connective tissue disease: A multicity study in Hubei province, China |
Cong Ye, Jixin Zhong, Shaozhe Cai, Li Dong, Chuanjing Li, Xiaoqiang Hou, Xiaoqi Chen, Anbing Zhang, Wenli Chen, Dongchu He, Tao Zhou, Guilian Shang, Aichun Chu, Huiling Li, Qihuan Liu, Bin Wu, Xiangdong Yu, Tao Peng, Cheng Wen, Gang Hong Huang, Hao Huang, Qin Huang, Linchong Su, Wenping Chen, Huiqin Yang, Lingli Dong |
| 74 |
[GO] |
2021―Jan―28 |
Use of SGLT-2 inhibitor in COVID-19: A cautionary tale |
Zohaib Yousaf, Waqar Munir, Riyadh Ali Mohammed Hammamy |
| 75 |
[GO] |
2021―Jan―21 |
Construction of a risk map to understand the vulnerability of various types of cancer patients to COVID-19 infection |
Jian He, Xufang Yang, Hui Wang |
| 76 |
[GO] |
2020―Nov―19 |
Middle-aged and elderly patients with COVID-19 pneumonia arising from asymptomatic carriers: A report of six cases |
Menglin Dai, Mulong Bao, Xian Chen, Qinxiu Zhang, Yimo Jian |
| 77 |
[GO] |
2020―Oct―12 |
Higher COVID-19 risk for patients with cancer |
Jincheng Yang, Zhe Chen, Bei Jia |
| 78 |
[GO] |
2020―Oct―01 |
Coronavirus in human diseases: Mechanisms and advances in clinical treatment |
Panpan Lin, Manni Wang, Yuquan Wei, Taewan Kim, Xiawei Wei |
| 79 |
[GO] |
2020―Sep―03 |
Measures taken to alleviate the impact of COVID-19 outbreak on surgical patients |
Xiang-Song Wu, Xu-An Wang, Xu-Heng Sun, Tai Ren, Li Zhao, Lin Shen, Yu-Rong Gong, Yan-Fei Xu, Shuai Huang, Ping Dong, Wei Gong, Xue-Feng Wang, Ying-Bin Liu |
| 80 |
[GO] |
2020―Aug―13 |
Radiomics-based model for accurately distinguishing between severe acute respiratory syndrome associated coronavirus 2 (SARS-CoV-2) and influenza A infected pneumonia |
Qi-Qiang Zeng, Kenneth I. Zheng, Jun Chen, Zheng-Hao Jiang, Tian Tian, Xiao-Bo Wang, Hong-Lei Ma, Ke-Hua Pan, Yun-Jun Yang, Yong-Ping Chen, Ming-Hua Zheng |
| 81 |
[GO] |
2020―Aug―06 |
Regulatory T cells: A potential weapon to combat COVID-19? |
Yu Liu, Guangying Qi, Joseph A. Bellanti, René Moser, Bernhard Ryffel, Song Guo Zheng |
| 82 |
[GO] |
2020―Jul―02 |
Neurologic manifestations of nonhospitalized patients with COVID-19 in Wuhan, China |
Hong Ding, Shanye Yin, Yahong Cheng, Yilun Cai, Weishan Huang, Wenjun Deng |
| 83 |
[GO] |
2020―Jun―19 |
Vitamin intervention for cytokine storm in the patients with coronavirus disease 2019 |
Jian-Sheng Kang |
| 84 |
[GO] |
2020―Apr―09 |
The Challenges of the COVID-19 Pandemic: Approaches for the Elderly and those with Alzheimer's Disease |
Qing Zhang, Weihong Song |
| 85 |
[GO] |
2020―Apr―08 |
Plasma therapy cured a COVID-19 patient with long duration of viral shedding for 49 days: the clinical features, laboratory tests, plasma therapy and implications for public health management |
Li Tan, Xia Kang, Bo Zhang, Shangen Zheng, Bo Liu, Tiantian Yu, Fan Yang, Qiongshu Wang, Hongming Miao |
|
